E-mail: trbusek.martin@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Assessment of p53 and ATM Functionality in Chronic Lymphocytic Leukemia By Multiplex Ligation-Dependent Probe Amplification
- ATM INACTIVATION DISTURBS ATM-P53 PATHWAY IN RESPONSE TO DNA DAMAGE INDUCED BY DOXORUBICIN BUT NOT FLUDARABINE IN CLL CELLS
- ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome
- BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNAS INDUCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS DURING ADMINISTRATION OF THERAPY IN VIVO AND IN VITRO
- CLL-SPECIFIC RESEQUENCING MICROARRAY AS A TOOL FOR CLL RESEARCH AND DIAGNOSTICS
- Clonal Evolution and Therapy Related Selection Of TP53 Mutations In Chronic Lymphocytic Leukemia Patients
- DEEP SEQUENCING IDENTIFIES TP53 MUTATIONS BEFORE THEIR CLONAL SELECTION BY THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Defects of ATM Gene Involving Mutation Lead to Complete Elimination of ATM Function in Chronic Lymphocytic Leukemia
- Detail Characterization of 22q11 Deletion and Mir-650 Role in CLL Patients
- DETAILED MUTATIONAL ANALYSIS OF TP53 GENE REVEALS HIGH INCIDENCE OF ADDITIONAL MINOR PROPORTION MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- DISTINCT FREQUENCY AND PROFILES OF TP53 GENE MUTATIONS IN CLL SUBGROUPS WITH DISTINCT ANTIGEN RECEPTORS: EVIDENCE FOR ANTIGEN-DRIVEN SELECTION OF GENOMIC ABERRATIONS
- ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET
- EVALUATION OF TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA USING RESEQUENCING MICROARRAY PLATFORMS
- GENOMIC COPY NUMBER ALTERATIONS IN HIGH-RISK CLL PATIENTS HARBORING TP53 DEFECTS: INSIGHTS FROM CONSECUTIVE INVESTIGATIONS
- High Expression of LAG3, LPL and ZAP-70 Genes in B-CLL Strongly Correlates with Unmutated IgVH and Early Therapy Requirement
- CHARACTERIZATION OF P53 AND ATM ABNORMALITIES IN B-CLL PATIENTS
- CHLORAMBUCIL (CHL) AND FLUDARABINE (F) AS A NEW PRE-TRANSPLANT CONDITIONING FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF IN VITRO AND IN VIVO EXPERIMENTS
- CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1
- INCORPORATION OF NEXT-GENERATION SEQUENCING INTO ATM GENE ANALYSIS IN PATIENTS WITH CLL AND MCL
- INHIBITION OF DNA-PK SENSITIZES A PROPORTION OF CLL CULTURES TO FLUDARABINE, REGARDLESS OF THE TP53/ATM STATUS
- Inhibition of Chk1 Kinase Sensitizes Leukemia and Lymphoma Cell Lines with TP53 Mutations to Chemotherapy
- Microrna-34a As a Marker for Fludarabine Resistance and Impairment of p53-Pathway in Chronic Lymphocytic Leukemia
- MICRORNA-34A IS SIGNIFICANTLY DOWN-REGULATED IN B-CLL PATIENTS WITH P53 ABNORMALITIES
- MICRORNAS EXPRESSION PATTERN IN AGGRESSIVE SUBTYPE OF CHRONIC LYMPHOCYTIC LEUKEMIA
- MISSENSE MUTATIONS LOCATED IN STRUCTURAL P53 DNA-BINDING MOTIFS ARE ASSOCIATED WITH EXTREMELY POOR SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Molekulárně-biologické přístupy mutační analýzy genu TP53 u onkologických pacientů.
- MONITORING OF THE STATUS OF BOTH P53 ALLELES IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RELEVANCE TO PROGNOSIS AND TREATMENT
- MUTATION STATUS OF ATM GENE IN CLL PATIENTS HARBORING DELETION 11Q OR TP53 DEFECT
- Mutational Analysis of Mir-29 Family Members in Chronic Lymphocytic Leukemia
- Mutational Analysis of TP53 Gene in Chronic Lymphocytic Leukemia: Comparison of Different Methodological Approaches
- MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA
- NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53- AND/OR ATM-DEFICIENT CELL LINES
- NOD/SCID IL2RGAMMA(-/-) XENOGRAFT MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA
- Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life
- P53 Inactivation and Genomic Aberrations in Relation to Imatinib Resistance in Chronic Myeloid Leukemia
- p53 Inactivation in CLL: Pattern of 110 TP53 Mutations
- PRESENCE OF HETEROZYGOUS ATM DELETION MAY NOT BE CRITICAL FOR THE RESPONSE OF CLL CELLS TO FLUDARABINE
- Prognostic Impact of NOTCH1 Hotspot Mutation in TP53-Mutated Patients with Chronic Lymphocytic Leukemia
- PROGNOSTICKÝ VÝZNAM HOT SPOT MUTACE GENU NOTCH1 U PACIENTŮ S CHRONICKOU LYMFOCYTÁRNÍ LEUKEMIÍ A SOUVISLOST S MOLEKULÁRNĚ BIOLOGICKÝMI MARKERY ONEMOCNĚNÍ
- Prognostický význam mutačního stavu genu TP53 u pacientů s B-buněčnou chronickou lymfocytární leukémií – význam monitorováni obou alel.
- Přítomnost heterozygotní delece ATM nedeterminuje odpověď CLL buněk na fludarabin
- REACTIVATION OF SELECTED P53 MUTANTS IN B-CELL TUMOR CELL LINES USING TARGETED SMALL MOLECULES
- REARRANGEMENT OF LAMBDA IMMUNOGLOBULIN LIGHT CHAIN IN CLL IS COUPLED WITH MIRNA-650 EXPRESSION
- RELATIONSHIP BETWEEN THERAPY AND CLONAL EVOLUTION OF TP53 ABNORMALITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Rituximab Sensitizes B-CLL Cells with Inactivated p53 to Fludarabine.
- RITUXIMAB SENSITIZES SOME B-CLL SAMPLES TO FLUDARABINE AND CHLORAMBUCIL IN VITRO, REGARDLESS OF P53/ATM STATUS
- Role of p53 Gene Mutation Type in B-CLL Prognosis
- SENSITIZATION OF LEUKEMIC CELLS TO FLUDARABINE BY MONOCLONAL ANTIBODY RITUXIMAB - IDENTIFICATION OF RESPONSIBLE GENES
- SESTŘIHOVÉ VARIANTY U PACIENTŮ S LYNCHOVÝM SYNDROMEM
- SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients
- SF3B1 MUTATIONS IN CLL ARE ASSOCIATED WITH A DEFECTIVE DNA DAMAGE RESPONSE
- SF3B1 MUTATIONS IN CLL ARE FUNCTIONALLY EQUIVALENT TO ATM GENE ALTERATIONS AND CAUSE DEFECTIVE PUMA AND P21 UPREGULATION IN RESPONSE TO DNA DAMAGE
- Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia
- Stanovení exprese ZAP-70 metodou kvantitativní cytometrie, korelace s mutačním stavem IgVH a expresí CD38 u pacientů s diagnózou B-CLL
- STUDIUM SELEKCE NEPŘÍZNIVÝCH GENOMICKÝCH ABNORMALIT V RELAPSU CHRONICKÉ LYMFOCYTÁRNÍ LEUKEMIE
- SYNTHETIC LETHALITY IN P53 MUTATED B-CELL MALIGNANCIES: CHK-1 INHIBITION AND DNA-PK INHIBITION EFFECT IN CELL LINES AND PRIMARY CLL CELLS
- T315I MUTATIONS ARE CLUSTERED WITH ADVANCED PHASES CONTRARY TO OTHER ABERRATIONS IN CML PATIENTS RESISTANT TO TKI THERAPY
- TARGETED NEXT-GENERATION SEQUENCING FOR MUTATIONAL SCREENING IN CHRONIC LYMPHOCYTIC LEUKEMIA: A HIGH-THROUGHPUT YET TAILORED APPROACH WILL FACILITATE IMPLEMENTATION WITHIN A CLINICAL SETTING
- Terapeutické monoklonální protilátky senzitivizují in vitro některé B-CLL vzorky s aberacemi genu TP53 k fludarabinu a chlorambucilu.
- Testování monoklonální protilátky rituximab u B-CLL buněk in vitro
- THE EXPRESSION OF A SINGLE MICRORNA - MIR-34A – IS A RELIABLE MARKER FOR IMPAIRMENT OF P53-PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- THE IMPACT OF SPECIFIC MUTATIONS IN TP53 GENE ON THE RESULTS OF ALEMTUZUMAB THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- The Regulation, Targets and Clinical Relevance of Microrna Mir-650 in Chronic Lymphocytic Leukemia (CLL)
- TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations
- TP53 MUTATIONS BUT NOT ATM MUTATIONS ASSOCIATE WITH HIGHER IN VITRO RESISTANCE OF CLL CELLS TO RITUXIMAB
- UNEXPECTED ANTAGONISTIC EFFECT OF RITUXIMAB WITH PROCARBAZINE DISCLOSED DURING AN IN VITRO TESTING OF RITUXIMAB-MEDIATED SENSITIZATION OF B-CELL LINES TO COMMONLY USED ANTICANCER DRUGS
- WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?
